About this trial
Ventricular tachycardia (VT) contributes to over 350,000 sudden deaths each year in the US. Malignant VTs involve an electrical "short circuit" in the heart, formed by narrow channels of surviving tissue inside myocardial scar. An important treatment is to use catheter ablation to "block" the channel that forms the circuit. Effective ablation requires imaging guidance to visualize the VT circuit relative to scar structures in 3D. Unfortunately, with conventional catheter mapping, up to 90% of the VT circuits are too short-lived to be mapped. For the 10% "mappable" VTs, their data are only available during ablation and limited to one ventricular surface. This inadequacy of functional VT data largely limits the knowledge about scar-related VT and ablation strategies, and reduces the ability of clinicians to identify ablation targets and assess ablation outcome.
The central hypothesis of this proposal is that functional VT data, integrated with CT or MRI scar data in 3D, can improve VT ablation efficacy with pre-procedural identification of ablation targets and post-procedural mechanistic elucidation of ablation failure. This research builds on the rapidly increasing clinical interest in electrocardiographic imaging (ECGi), an emerging technique that obtains cardiac electrical activity through inverse reconstructions from ECGs. The specific objective is to push the boundary of ECGi to provide - as a conjunction to intra-procedural catheter mapping - pre-ablation and post-ablation imaging of functional VT circuits integrated with 3D scar structure.
Eligibility criteria
Qualifiers
One or more episodes of sustained monomorphic VT
Referred for catheter ablation
Previously implanted ICD
Signed the patient informed consent form
Disqualifiers
Have estimated Glomerular Filtration Ratio (eGFR) less than 30
Have a life expectancy less than 6 months or are listed for heart transplantation at time of inclusion
Are pregnant
Are on IV inotropic agents
Trial design
Treatments tested in this trial
- EP Imaging and Testing
Treatment groups
Sponsors and collaborators
John Sapp
Lead sponsor
Nova Scotia Health Authority
Sponsor institution
Nova Scotia Health Authority
Collaborator
Rochester Institute of Technology
Collaborator